PathwayClinical Pathway for Management of Suspected or Positive Novel Coronavirus-19 Patients With ST-Segment Elevation Myocardial InfarctionRanard, Lauren S. MD*; Ahmad, Yousif MD*; Masoumi, Amirali MD*; Chuich, Taylor PharmD*; Romney, Marie-Laure S. MD, MBA†; Gavin, Nicholas MD, MBA, MS†; Sayan, Osman R. MD†; Kirtane, Ajay J. MD, SM*; Rabbani, LeRoy E. MD*Author Information From the *Department of Medicine, Division of Cardiology, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY †Department of Emergency Medicine, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY. Received for publication April 2, 2020; accepted April 5, 2020. Dr. Kirtane reports institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, Philips, and ReCor Medical. Personal: Continuing Medical Education (CME)/conference honoraria and travel/meals only. Reprints: LeRoy E. Rabbani, MD, Division of Cardiology, Department of Medicine, NewYork-Presbyterian/Columbia University Irving Medical Center, 173 Fort Washington Avenue, New York, NY 10032. E-mail: firstname.lastname@example.org. Critical Pathways in Cardiology: June 2020 - Volume 19 - Issue 2 - p 49-54 doi: 10.1097/HPC.0000000000000223 Buy Metrics Abstract Novel coronavirus-19 disease (COVID-19) is an escalating, highly infectious global pandemic that is quickly overwhelming healthcare systems. This has implications on standard cardiac care for ST-elevation myocardial infarctions (STEMIs). In the setting of anticipated resource scarcity in the future, we are forced to reconsider fibrinolytic therapy in our management algorithms. We encourage clinicians to maintain a high level of suspicion for STEMI mimics, such as myopericarditis which is a known, not infrequent, complication of COVID-19 disease. Herein, we present a pathway developed by a multidisciplinary panel of stakeholders at NewYork-Presbyterian/Columbia University Irving Medical Center for the management of STEMI in suspected or confirmed COVID-19 patients. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.